Neurocognitive effects of androgen deprivation therapy and new hormonal agents in a sample of patients with metastatic prostate cancer

CONCLUSIONS: Treatment of mPC with ADT is correlated with neurocognitive deficits in several cognitive domains. Language skills and processing speed were most frequently impaired. However, a consistent pattern of cognitive impairment was not identified. Neurocognitive deficits should be considered in phase III and IV trials.TRIAL REGISTRATION: The study was registered in the German Clinical Trials Registry (DRKS00017727).PMID:37466904 | DOI:10.1007/s11255-023-03712-z
Source: Methods of Information in Medicine - Category: Information Technology Authors: Source Type: research